[A19-15] Lenvatinib (hepatocellular carcinoma) - Addendum to Commission A18-57

Last updated 22.03.2019

Project no.:
A19-15

Commission:
Commission awarded on 12.03.2019 by the Federal Joint Committee (G-BA).

Report type:
Addendum

Status:
Commission completed

Department/Division:
Drug Assessment

Application field:
Cancer

Indication:

Adult patients with advanced or unresectable hepatocellular carcinoma who have received no prior systemic therapy

Result of dossier assessment:

Added benefit still not proven for both research questions after analysis of further data

Note:

If the need for additional work on a project commissioned by the G-BA arises during consultations, then IQWiG presents a report in the form of an "addendum". The G-BA subsequently decides on the extent of the added benefit, thus completing the early benefit assessment.

Accompanying information

Further information for consumers and patients is provided on IQWiG's health information website www.informedhealth.org.

Federal Joint Committee (G-BA)

2019-03-22 A G-BA decision was published.

G-BA documents on this decision

Contact

Info Service

Subscribe to daily updated information on projects, calls for tender, and events as well as our press releases.

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.